Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Under Commissioner’s National Priority Voucher Pilot Program Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company pioneering the development of targeted therapies…
Grifols Strengthens U.S. Diagnostic Manufacturing with New San Diego Facility Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company specializing in plasma-derived medicines and innovative diagnostic solutions, has officially commenced production at its newly inaugurated facility in…
Taiho Pharma and Haihe Biopharma Form Exclusive Japanese Partnership for PI3Kα Inhibitor Risovalisib Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement for the development, manufacturing, and commercialization of…
Veradermics Secures $150M Series C to Advance Oral Hair Regrowth Therapy Connecticut-based biotech Veradermics has raised $150 million in an oversubscribed Series C funding round to advance its oral hair regrowth therapy, VDPHL01, through late-stage clinical development and regulatory submission.…
CVS Health Expands Access to Affordable Fertility Treatments Nationwide CVS Health (NYSE: CVS) has announced a major step toward improving access to fertility care and making fertility treatments more affordable for Americans. Through its CVS Specialty Pharmacy network and more…
Merck’s Phase 3 KEYNOTE-B96 Trial Achieves Key Milestone in Platinum-Resistant Ovarian Cancer, Demonstrating Survival Benefit in All-Comer Population Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that its pivotal Phase 3 KEYNOTE-B96 (ENGOT-ov65) clinical…
Digitail and CDMV Partner to Streamline Veterinary Operations and Improve Patient Care Across Canada Digitail, the industry’s leading AI-native veterinary practice information management system (PIMS), has announced a strategic integration and go-to-market partnership with CDMV, Canada’s premier distributor and service…
Music Industry Icons Unite to Celebrate Tom Corson at City of Hope’s Spirit of Life Gala, Raising Funds to Advance Cancer Research, Survivorship Programs, and Integrative Therapies one of the largest and most advanced cancer research and treatment organizations in…
SelectQuote Research Reveals Critical Gaps in Medicare Care, Underscoring Need for Personalized Healthcare Solutions OVERLAND PARK, Kan.–(BUSINESS WIRE)–SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and the owner of a rapidly expanding healthcare services platform, today published…
Regeneron Unveils Key Oncology Pipeline Updates at ESMO 2025, Highlighting Patient-Centric Approaches for Hard-to-Treat Cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its oncology pipeline will be presented in seven abstracts at the European…
Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced new results from its Phase…
Novo Nordisk Acquires Global Rights to Omeros’ MASP-3 Inhibitor Zaltenibart in $2.1 Billion Agreement Novo Nordisk and Omeros Corporation (Nasdaq: OMER) have entered into a definitive asset purchase and license agreement for zaltenibart (formerly OMS906), a clinical-stage antibody targeting MASP-3…